Abstract:Background: Although JAK (Janus Kinase) inhibitors have been widely applied to many types of aggressive tumors with continuously activated JAK/STAT signaling pathways, efficacious compounds against cervical cancer (CC) are still lacking, and chronic exposure to them inevitably results in drug resistance that often arises from compensatory activation of alternative signaling and survival pathways. Therefore, developing novel JAK inhibitors and identifying their partner compounds for combination therapy against CC, remains an unmet clinical need.Methods: In this study, by virtual screening the SPECS database, we selected out multiple JAK inhibitor candidates, validated their kinase activities and antitumor drug efficacies in various biochemical, cellular and in vivo xenograft models. Next, we screened a chemical library containing 2094 small molecules to identify compounds that act synergistically with the best JAK inhibitor obtained above in dampening CC cell propagation. Finally, the molecular mechanism of such synergistic effect was explored.Findings: Twenty potential small-molecule JAK inhibitors were identified by virtual screening, and the top 9 ranking compounds were validated by biochemical assays. AH057, the best JAK inhibitor identified, can effectively block JAK/STAT pathways by directly inhibiting JAK1/2 activities, and exhibits potent antitumor effects including compromised cell proliferation and invasion, increased apoptosis, arrested cell cycles and impaired tumor progression in a xenograft model. Among all cell lines examined, CC cell lines were the most sensitive to AH057. Further, based on the calculated Bliss synergy scores, SGI-1027, a DNMT1 inhibitor, was identified as the best compound that works in high synergy with AH057. The combination of AH057 and SGI-1027 potently induced cell cycle arrest at G1 phase partially through Cyclin D1 and Cyclin A2, and apoptotic cell death that is linked to PARP, Caspase-3, Bcl-xL and Survivin.Interpretation: A novel oral small-molecule JAK1/2 inhibitor AH057 with definitive antitumor efficacy against CC is identified in this study. The combination of AH057 with the DNMT1 inhibitor SGI-1027 synergistically impairs cancer cell propagation via induced apoptosis and cell cycle arrest, likely by acting on a same group of downstream effector molecules that are dually controlled by JAK1/2 and DNMT1. This study provides preclinical support for launching a clinical trial to evaluate the safety and efficacy of this drug combination in patients with CC and other malignant tumors.Funding Statement: This work was supported by grants from the National Key Research and Development Program of China (2016YFA0101201, 2016YFA0100303, 2017YFD0200505), and the National Natural Science Foundation of China (31601103, 31872022).Declaration of Interests: YJW, BK and JZ have a pending patent application titled “Identification of a novel JAK1/2 inhibitor and its synergistic drug combinations against human cancers”. The other authors declared no conflicts of interest.Ethical Approval Statement: The Experimental Animal Ethics Committee of Zhejiang University has approved the animal protocol.

A Jak2-selective Inhibitor Potently Reverses the Immune Suppression by Modulating the Tumor Microenvironment for Cancer Immunotherapy

Remodeling Tumor-Associated Macrophage for Anti-Cancer Effects by Rational Design of Irreversible Inhibition of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2

Identification of a Novel Oral Small-Molecule JAK1/2 Inhibitor and Its Potent Synergistic Drug Combinations Against Cervical Cancer

Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

Targeting JMJD1C to Selectively Disrupt Tumor Treg Cell Fitness Enhances Antitumor Immunity

Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

Targeting JMJD1C to selectively disrupt tumor T reg cell fitness enhances antitumor immunity

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

Reactivating antitumor immunity by inhibiting JMJD1C

Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy

BET Inhibitor JQ1 Selectively Reduce Tregs by Upregulating STAT3 and Suppressing PD-1 Expression in Patients with Multiple Myeloma.

Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer

A JAK Tyrosine Kinase and Pseudokinase Co-inhibition Strategy Combines Enhanced Potency and On-Demand Activation

Totipotent "All‐in‐one" Peptide Sequentially Blocks Immune Checkpoint and Reverses Immunosuppressive Tumor Microenvironment

IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma

Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy.

Targeted SPP1 Inhibition of Tumor‐Associated Myeloid Cells Effectively Decreases Tumor Sizes

PIM2 expression induced by proinflammatory macrophages suppresses immunotherapy efficacy in hepatocellular carcinoma